• Breaking News

    Wednesday, June 2, 2021

    Home Unlabelled Stock Market - Arrrrrrrghh!

    Stock Market - Arrrrrrrghh!

    June 02, 2021

    Stock Market - Arrrrrrrghh!

    Arrrrrrrghh!

    Posted: 02 Jun 2021 03:20 PM PDT

    AMC HALTED

    Posted: 02 Jun 2021 09:31 AM PDT

    Hodl the line!!!!!!!

    Posted: 02 Jun 2021 12:33 PM PDT

    Damn dirty apes!

    Posted: 02 Jun 2021 03:27 PM PDT

    AMC up 40% as Reddit bulls drown out hedge fund share dump

    Posted: 02 Jun 2021 04:34 AM PDT

    https://finance.yahoo.com/news/amc-shares-set-record-open-090728942.html

    Wed, June 2, 2021, 5:07 AM

    (Reuters) -Shares of AMC Entertainment surged another 38% in early deals on Wednesday and were set to open at a record high as individual traders on social media forums were unfazed by a hedge fund flipping its stake in AMC, calling it overvalued.

    Hedge fund Mudrick Capital Management sold 8.5 million freshly issued AMC shares at a profit on Tuesday, a source said, immediately after buying them. AMC had earlier said it was prepared to make acquisitions with the new issuance, worth about $230.5 million.

    Extending a red hot rally, the cinema operator's stock traded at $41.90 on Wednesday, leading gains among the group of "meme stocks" including video game retailer GameStop Corp and BlackBerry Ltd that have attracted the attention of small-time traders on online platforms such as Reddit's WallStreetBets.

    "It's not rational, but do not bet against it," said a Berlin-based trader.

    AMC's stock has surged more than 1,400% this year and, at nearly $42, is trading at more than 10 times the median analyst price target.

    The number of messages related to AMC on trading-focused social media site Stocktwits rose more than 7% on Wednesday, with most of them reflecting a positive sentiment.

    AMC daily stock trading volumes in the past week have reached their highest since January, according to Refinitiv Eikon, while data from Fidelity showed it continued being the brokerage platform's most traded scrip.

    GameStop was up 4.5% in premarket trading, while Koss Corp jumped 13%. BlackBerry's U.S.-listed shares were last up 18.6%, bringing their total yearly gains to more than 75%.

    (Reporting by Sagarika Jaisinghani and Aaron Saldanha in Bengaluru and Thyagaraju Adinarayan in London; Editing by Sriraj Kalluvila and Shounak Dasgupta)

    submitted by /u/SavannahSmiles_
    [link] [comments]

    Blackberry to the moon!!!

    Posted: 02 Jun 2021 02:08 PM PDT

    Too true ����‍♂️ ��‍♀️ �� ��

    Posted: 02 Jun 2021 12:36 PM PDT

    The Legend Grows ($50+)

    Posted: 02 Jun 2021 09:23 AM PDT

    Retarded. But rich retarded

    Posted: 02 Jun 2021 07:18 PM PDT

    AMC up 2300% in 2021

    Posted: 02 Jun 2021 09:08 AM PDT

    Who else is using the Fidelity beta now, and just how excited are you?? RH: Eat. Your. Heart out.

    Posted: 02 Jun 2021 05:42 PM PDT

    It’s been a good day, wish I had more but don’t we all

    Posted: 02 Jun 2021 02:10 PM PDT

    AMC through the Stratosphere

    Posted: 02 Jun 2021 11:27 AM PDT

    Me @ Brokers freezing AMC now

    Posted: 02 Jun 2021 02:12 PM PDT

    Ally Bank ends all overdraft fees, first large bank to do so

    Posted: 02 Jun 2021 12:45 PM PDT

    $F Ford stock rally

    Posted: 02 Jun 2021 08:48 AM PDT

    Ford stock is rallying this week with the new electric lighting being unveiled. 300mi range for a electric truck is impressive. Bronco off-roading school has also started and the new EV mustang is the #1 selling car in Norway. It also looks like their earnings are up this quarter a good percentage. Ford has been in the news a bit recently as well with a new aluminum quarter paneling and riveting technology they spent a good bit of money on. Anyone else looking at this stock? I've been holding around 200 shares for a while, average about 6.16 a share (bought Covid dip). Do y'all think it will keep up with Fords positive outlook in the EV market with lighter aluminum and good range?

    submitted by /u/mfreestyle101
    [link] [comments]

    AMC: Hedge Fund 1-0 Reddit Army

    Posted: 02 Jun 2021 12:45 PM PDT

    Today's Top Gainers for June 2nd - Shows Just How Massively Big Money is overleveraged with these Short Positions. There are a couple exceptions in the group, but I suspect the majority having heavy short manipulation. In turn - I believe if any of these are tied together... Maybe a BIG SHORT.

    Posted: 02 Jun 2021 07:51 PM PDT

    Buy and hold good companies. Worked with my dad over the summer of 2012 when I was 16 and used some of the $ for that crazy MySpace clone.. worked out well.

    Posted: 01 Jun 2021 08:13 PM PDT

    Amc halt trading only because of volatility don't panic it normal it happens every day to over ticker ... hodl strong my fellow apes AMC to the moon... AMC50k

    Posted: 02 Jun 2021 10:59 AM PDT

    S&P Rolling Returns - 10 Year Annual Total Returns

    Posted: 02 Jun 2021 12:53 PM PDT

    All IN..let's goooo, apes

    Posted: 02 Jun 2021 02:15 PM PDT

    GTHX - ASCO21 as cancer biotech catalyst

    Posted: 02 Jun 2021 08:40 AM PDT

    GTHX - ASCO21 as cancer biotech catalyst

    G1 will present 3 posters at ASCO21, one at session about Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers , and two posters on session about Metastatic Breast Cancer!

    http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-announces-upcoming-data-american-society Two of this poster session will be about trilaciclib - is the first and only FDA-approved therapy to provide myeloprotective efficacy, and one will present new data about - RINTODESTRANT.

    Rintodestrant is SERD https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader And its possible to become one the best in SERD lineup because of it's combination. Rintodestrant is used in combination with palbociclib (https://en.wikipedia.org/wiki/Palbociclib) and first results were very optimistic! For the ASCO21 G1 Therapeutics will present a new data about phase 1. For this moment what we should know about Rintodestrant poster that will be presented at ASCO (https://meetinglibrary.asco.org/record/198202/abstract)

    BACK IN TIME

    Here is the GTHX price graphic after ESMO 2019 (European Society for Medical Oncology) where were presented first results about rintodestrant.

    ESMO 2019 reaction

    Presented clinical benefit (i.e. the number of patients who observed complete response + partial response + disease stabilization for at least 24 weeks) at all doses was only 15.8%, or only 3 out of 19 patients who received G1T48 (working name of rintodestrant). The effect was not impressive. Here is the poster that was presented https://www.g1therapeutics.com/file.cfm/34/docs/48-G1_ESMO2019_Dees.pdf

    The market now has the undisputed leader in the class of selective biodegradants of estrogen receptors - this is Fulvestrant from $AZN (FASLODEX) . If the Rintodestrant by some chance can give a hint on June 4th that he is ready to break into this segment - a roller coaster awaits us on SERD market! For this moment SERD market coast at $ 4 billion by 2030 (https://www.prnewswire.com/news-releases/global-4-billion-serd-therapeutics-market-to-2030-faslodex-rad1901-gdc-9545-azd9833-sar439859-301279118.html)

    THE ASCO21 EXPECTATION

    Rintodestant a potent, oral selective estrogen receptor degrader, competitively binds and degrades the estrogen receptor (ER), thus blocking ER signaling in tumors resistant to other endocrine therapies (ET). Results from parts 1 and 2 dose-escalation/expansion indicate that once-daily (QD) rintodestrant has a favorable safety profile and antitumor activity in patients (pts) with heavily pretreated ER+/HER2– advanced breast cancer (ABC), including those with ESR1 variants (Aftimos et al. SABCS 2020 [PS12-04, PD8-07]). The optimal dose of rintodestrant was 800 mg. Here, we present part 3, combining rintodestrant with the CDK4/6 inhibitor palbociclib.

    The methods of using: This open-label study evaluated rintodestrant in pts with ER+/HER2– ABC after progression on ET NCT03455270. Part 3 assessed rintodestrant 800 mg QD + palbociclib 125 mg QD for 21 days every 28 days. Key eligibility criteria included ≤1 line of chemotherapy and/or ≤1 line of ET in the advanced setting, with ≥6 months of ET in the advanced setting and/or ≥24 months in the adjuvant setting. Prior CDK4/6 inhibitor therapy was not allowed. Primary objectives included safety and efficacy. Secondary objectives included pharmacokinetics and antitumor activity (RECIST v1.1). Exploratory objectives included mutation profiling (cell-free DNA) at baseline and cycle 1 day 15.

    Results: Enrollment occurred Jul–Oct 2020. As of Dec 9, 2020, 40 pts were treated, with a median age of 58 years (35–76) and ECOG PS of 0 (70%) or 1 (30%); 20% had de novo stage 4 disease, 10% bone-only, and 68% visceral metastases. Median number of visceral sites was 1 (0–3): 30% of pts with lung and 40% with liver involvement. Median number of prior lines in the advanced setting was 1 (0–2), including chemotherapy (48%), fulvestrant (15%), and aromatase inhibitors (50%). Most recent ET was given in the adjuvant and metastatic settings in 28% and 73% of pts, respectively. Rintodestrant-related adverse events (AEs) were reported in 8% of pts—all nonserious and grade 2—and included nausea (3%), vomiting (3%), and neutropenia (3%). The most common (≥10%) treatment-related AEs (rintodestrant and/or palbociclib) were neutropenia (88%), leukopenia (45%), anemia (10%), and thrombocytopenia (10%); grade 3/4 neutropenia was 38%/15%, in line with the safety profile of palbociclib. No deaths or treatment discontinuations due to AEs were reported. At data cutoff (median treatment duration of 3 months [1.5–4.6]), 28 pts (70%) remained on study treatment, 2 (5%) had a confirmed partial response, and 27 (68%) had stable disease. Additional efficacy and pharmacodynamic data will be presented.

    Conclusions: Rintodestrant, as monotherapy or combined with palbociclib, continues to demonstrate an excellent safety/tolerability profile with promising antitumor activity in pts with ER+/HER2– ABC, including those with ESR1 variants. Clinical trial information: NCT03455270.

    PIPELINE AND FUTURE

    For this moment G1 have COSELA (trilaciclib) as potential market golden egg because of chemoterapy, it was approved by FDA in february and in 1Q 2021 it already made 600k of revenue on 30 patients with SCLC! Cosela included in two NCCN guidelines for Small Cell Lung Cancer treatment! Now it will be tested and used with Colorectal, Breast and Bladder cancer too.

    Medicare and Medicaid will include Cosela in list of medication that will need clininc-administred requiring prior autorization. Some of insurance companies already did it (BCBS NC, BCBS Michigan, Anthem CA, Oregon Health Department approved Cosela for Medicaid)

    Internationally G1 have strong market side, maybe the one of the biggest market of chemotherapy is China! Simcere as partner of G1 sold some genetics companies to make free money and power up with trilaciclib in China, on may 25 in Jilin Cancer Hospital - China, was first patient with SCLC treated with COSELA! In april started 3 phase for colorectal cancer with trilaciclib and folfoxiri/becacizumab!

    And latest news from China:
    http://hk.jrj.com.cn/2021/06/02145232863127.shtml
    Simcere Pharmaceutical (02096) cooperated with Hainan Boao Hengda International Hospital to use Trilaciclib for the first clinical treatment of Chinese patients
    Zhitong Finance A PP learned that on June 2, Simcere Pharmaceutical (02096) and Hainan Boao Hengda International Hospital announced that Trilaciclib, a new drug that had been approved by the FDA as a breakthrough therapy, had been approved by the Hainan Provincial Drug Administration. The Boao Lecheng International Medical Tourism Pilot Zone was used for clinical application, and the first domestic prescription was issued at Boao Evergrande International Hospital, and the first clinical administration for patients with extensive-stage small cell lung cancer (ES-SCLC) was completed.

    ​

    G1 Therapeutcs pipeline

    Opinion

    ASCO21 could become a real catalyst action for G1 if the rintodestrant does not show outstanding results, it is quite possible that the company's shares will collapse by $ 5-10

    With a successful presentation, it is difficult to predict growth, but possible it will be 25$ per shares, in the last week G1 shares were bought in large volumes, at the end of the session!

    ​

    153% of average volume and closing price GTHX

    And some technicall analysis from
    https://bovnews.com/2021/05/31/why-g1-therapeutics-inc-gthx-and-mcdonalds-corporation-mcd-looks-good-at-the-present-situation/

    In the most recent purchasing and selling session, G1 Therapeutics Inc. (GTHX)'s share price decreased by -2.29 percent to ratify at $21.72. A sum of 1655141 shares traded at recent session and its average exchanging volume remained at 1.06M shares. The 52-week price high and low points are important variables to concentrate on when assessing the current and prospective worth of a stock. G1 Therapeutics Inc. (GTHX) shares are taking a pay cut of -41.41% from the high point of 52 weeks and flying high of 100.93% from the low figure of 52 weeks.

    G1 Therapeutics Inc. (GTHX) shares reached a high of $23.085 and dropped to a low of $21.52 until finishing in the latest session at $22.38. Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Currently at 1.17 is the 14-day ATR for G1 Therapeutics Inc. (GTHX). The highest level of 52-weeks price has $37.07 and $10.81 for 52 weeks lowest level. The liquidity ratios which the firm has won as a quick ratio of 11.50, a current ratio of 11.60 and a debt-to-equity ratio of 0.12.

    Having a look at past record, we're going to look at various forwards or backwards shifting developments regarding GTHX. The firm's shares rose 2.65 percent in the past five business days and shrunk -0.91 percent in the past thirty business days. In the previous quarter, the stock fell -5.85 percent at some point. The output of the stock increased 59.12 percent within the six-month closing period, while general annual output gained 27.99 percent. The company's performance is now positive at 20.73% from the beginning of the calendar year.

    According to WSJ, G1 Therapeutics Inc. (GTHX) obtained an estimated Buy proposal from the 8 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. 0 equity research analysts rated the shares with a selling strategy, 0 gave a hold approach, 7 gave a purchase tip, 1 gave the firm a overweight advice and 0 put the stock under the underweight category.

    Finally...

    My vision is that rintodestrant is effective with palbociclib which is Pfizer product and i expect that G1 will sold the rights for rintodestrant as it was made with lerociclib before! The new scientific and clinical trials will cost a lot of money and G1 understand that. Possible solution to sold rights will give money for new researches with trilaciclib and make investors feel safety , because if G1 will have enough money for future there will be no possible scenario about stock dilution wich is very popular for small cap biotech companies!

    RothCapital G1 future

    ​

    For this moment the SERD market is very tough place to be! Rintodestrant is one of the top as G1 says, but the results once were very unattractive and possible bad presentation could fail G1 stocks to 11-14$ and this could be my possibility to buy more)

    SERD market

    But if the rintodestrant+palbociclib will made a great start at ASCO21 there is a possible growth to 27-30$!

    The best way for short and mid term is to but it before ASCO in case of good results it will give 7-10% of growth easily! Or to open short position in case of bad data results!

    In term of long term traiding buy and forget about it for 2-3 years! But still there is a possibility of buying by another company, like it happened today with CNST! Btw i made 65% of profit in 6 days on this stock!

    submitted by /u/appolomustdie
    [link] [comments]

    They did it again..

    Posted: 02 Jun 2021 09:38 AM PDT
    Read more
    at

    No comments:

    Post a Comment